Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Dow
Cantor Fitzgerald
Healthtrust
AstraZeneca
Queensland Health
Cipla
Citi

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,795,911

« Back to Dashboard

Which drugs does patent 5,795,911 protect, and when does it expire?

Patent 5,795,911 protects VEREGEN and is included in one NDA.

This patent has thirteen patent family members in nine countries.
Summary for Patent: 5,795,911
Title: Composition for treating Condyloma acuminata
Abstract:A composition for a treatment of HPV-infected Condyloma acuminata which comprises containing tea catechin as a main component. This medication has no danger of side-effects and may be easily applied to or inserted in the infected area by the patient themselves.
Inventor(s): Cheng; Shu Jun (Beijing, CN), Wang; De Chang (Beijing, CN), Hara; Yukihiko (Fujieda, JP)
Assignee: Cancer Institute (Hospital), Chinese Academy of Medical Sciences (Beijing, CN) Mitsui Norin Co., Ltd. (Tokyo, JP)
Application Number:08/835,920
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 5,795,911

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Fougera Pharms Inc VEREGEN sinecatechins OINTMENT;TOPICAL 021902-001 Oct 31, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF GENITAL WARTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,795,911

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-321195Nov 18, 1996

Non-Orange Book US Patents Family Members for Patent 5,795,911

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,968,973 Method for treating hyperplasia ➤ Sign Up
6,197,808 Methods for treating hyperplasia ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Army
Colorcon
Teva
Accenture
Merck
Chubb
QuintilesIMS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.